Chris Francis - 16 Oct 2024 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
SVP, Corporate Development, Head of Emerging Areas
Signature
/s/ Chris Francis
Issuer symbol
WVE
Transactions as of
16 Oct 2024
Net transactions value
-$2,483,641
Form type
4
Filing time
18 Oct 2024, 20:00:04 UTC
Previous filing
07 Feb 2024
Next filing
13 Nov 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Sale $1,115,996 -79,714 -100% $14.00 0 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Options Exercise $101,673 +40,997 $2.48 40,997 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Sale $532,961 -40,997 -100% $13.00 0 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Options Exercise $206,062 +65,625 $3.14 65,625 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Sale $902,344 -65,625 -100% $13.75 0 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Options Exercise $63,675 +22,500 $2.83 22,500 16 Oct 2024 Direct F1
transaction WVE Ordinary Shares Sale $303,750 -22,500 -100% $13.50 0 16 Oct 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Options Exercise $0 -40,997 -100% $0.000000 0 16 Oct 2024 Ordinary Shares 40,997 $2.48 Direct F2
transaction WVE Share Option (right to buy) Options Exercise $0 -65,625 -44% $0.000000 84,375 16 Oct 2024 Ordinary Shares 65,625 $3.14 Direct F3
transaction WVE Share Option (right to buy) Options Exercise $0 -22,500 -50% $0.000000 22,500 16 Oct 2024 Ordinary Shares 22,500 $2.83 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
F2 The share options that were exercised in this reportable transaction were fully vested.
F3 The share option represented the right to purchase a total of 150,000 ordinary shares, 25% of which became exercisable on January 1, 2023, and the remaining shares vest as to an additional 6.25% quarterly thereafter until January 1, 2026.

Remarks:

SVP, Corporate Development, Head of Emerging Areas